Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.1.9
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Unaudited Consolidated Statements Of Operations    
Revenues      
Operating expenses:    
Amortization & depreciation 184us-gaap_DepreciationAndAmortization 194us-gaap_DepreciationAndAmortization
General and administrative 85,271us-gaap_GeneralAndAdministrativeExpense 138,626us-gaap_GeneralAndAdministrativeExpense
Total operating expenses 85,455us-gaap_OperatingExpenses 138,820us-gaap_OperatingExpenses
Loss from operations (85,455)us-gaap_OperatingIncomeLoss (138,820)us-gaap_OperatingIncomeLoss
Other income (expense):    
Gain/(Loss) on fair value adjustment - derivatives 25,456IMLE_LossOnFairValueAdjustmentDerivatives (10,051)IMLE_LossOnFairValueAdjustmentDerivatives
Interest expense (55,414)us-gaap_InterestIncomeExpenseNet (41,854)us-gaap_InterestIncomeExpenseNet
Interest expense - beneficial conversion feature (3,750)us-gaap_InterestExpense (10,664)us-gaap_InterestExpense
Total other income (expense) (33,708)us-gaap_NonoperatingIncomeExpense (62,569)us-gaap_NonoperatingIncomeExpense
Loss before provision for income taxes (119,163)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (201,389)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Provision for income tax      
Net loss (119,163)us-gaap_ProfitLoss (201,389)us-gaap_ProfitLoss
Less: Net loss attributable to noncontrolling interest 934us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 1,194us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net loss attributable to TranBioTec, Inc. $ (118,229)us-gaap_NetIncomeLoss $ (200,195)us-gaap_NetIncomeLoss
Net loss per share    
(Basic and fully diluted) $ (0.003)us-gaap_EarningsPerShareBasicAndDiluted $ (0.006)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average number of common shares outstanding 39,215,919IMLE_WeightedAverageNumberOfCommonSharesOutstanding 35,007,823IMLE_WeightedAverageNumberOfCommonSharesOutstanding